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Objective: The incidence of heparin-induced thrombocytopenia is increasing, and
the thrombin inhibitor danaparoid could be a useful alternative. The objective of the
present study was to compare danaparoid and heparin in patients undergoing
off-pump coronary artery bypass grafting.
Methods: In a prospective, randomized, double-blind clinical trial comparing hep-
arin (bolus of 1 mg/kg) with danaparoid (bolus of 40 U/kg), 71 patients underwent
off-pump coronary artery bypass grafting with one of the study drugs. The amount
of blood lost, the number of homologous blood products transfused, the troponin T
levels, and the amount of anti-Xa activity were monitored.
Results: Thirty-four patients underwent 2.6 0.7 bypasses with danaparoid, and 37
patients underwent 2.5  0.9 grafts with heparin (P  .8). Postoperative blood
losses averaged 1394  1033 mL in patients receiving danaparoid and 1130  868
mL in patients receiving heparin (P  .2). The number of homologous blood
products transfused averaged 3.6  7 units in patients receiving danaparoid and
1.9  4.4 units in patients receiving heparin (P  .2). The number of patients
requiring homologous blood transfusion was higher in patients receiving danaparoid
(18/34 [53%]) than in patients receiving heparin (10/37 [27%], P  .03). Serum
anti-Xa activity averaged 1.6  0.6 U/mL in patients receiving danaparoid and
1.9  0.8 U/mL in patients receiving heparin 30 minutes after injection of the drugs
(P  .1) and 0.3  0.1 and 0.04  0.08 U/mL, respectively, 12 hours after coronary
artery bypass grafting (P  .001). Troponin serum levels were similar 48 hours after
coronary artery bypass grafting (0.5  0.6 and 0.4  0.6 g/L, respectively).
Conclusion: Although off-pump coronary artery bypass grafting with danaparoid
versus heparin increases the number of patients exposed to homologous blood
transfusion (relative risk, 2; 95% confidence limits, 1-4), off-pump coronary artery
bypass grafting with danaparoid is a valuable alternative to heparin in patients with
thrombocytopenia requiring surgical intervention.
Unfractionated heparin is the standard anticoagulant in patientsundergoing cardiopulmonary bypass (CPB).1 There are very fewcontraindications to the use of standard heparin, but heparin-induced thrombocytopenia (HIT) is emerging as a significantcomplication.2 Although the incidence of this immune-mediatedreaction to heparin appears low (between 1% and 2%), the risk of
thrombotic complications is well documented.3,4 Because most patients with unsta-
ble angina are administered intravenous heparin for the medical management of the
condition, heparin-associated thrombocytopenia is frequently recognized before
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coronary bypass grafting surgery. Thus, several investiga-
tors have attempted to find alternatives to heparin in patients
undergoing CPB.5,6
Danaparoid, a heparin-free mixture of glycosaminogly-
cans derived from the porcine intestinal mucosa, was sug-
gested as an alternative to heparin in patients with HIT who
underwent CPB.2 Danaparoid offers several advantages,
such as a more specific inhibition at the Xa level compared
with that produced with heparin and a lower cross-reactivity
with the heparin-induced antibodies compared with that
seen with low-molecular-weight heparins. Also, danaparoid
has several disadvantages, such as the lack of a direct
neutralizing agent and a long half-life of 25 hours.7 More-
over, the use of danaparoid and of all alternative agents to
heparin during CPB has been associated with serious post-
operative bleeding complications.1,2
Although off-pump coronary artery bypass grafting
(OPCABG) is widely performed in several institutions, the
exact role and indications for the procedure remain unde-
fined.8 Several authors have suggested that OPCABG could
especially benefit patients at high risk of complications
related to the use of the CPB system.9 OPCABG in patients
with HIT could be an alternative to conventional coronary
artery bypass grafting (CABG) with CPB if a valuable
alternative to heparin could be used. Thus, we suggest that
a low-dose administration of danaparoid in OPCABG is a
valuable alternative to the use of heparin.
We therefore undertook a double-blind, prospective, ran-
domized clinical trial to compare the anticoagulants danap-
aroid and heparin in patients undergoing OPCABG surgery.
The primary objective of the study was to compare blood
loss in patients undergoing OPCABG with standard heparin
versus danaparoid. The secondary aim of the study was to
determine the effect of the 2 drugs on the percentage of
patients requiring any type of homologous blood product
transfusions and the number of blood product units trans-
fused per patient after surgical intervention. Finally, we
looked to compare the safety of the 2 drugs by measuring
antithrombotic effects and overall myocardial ischemic
damage.
Methods
Study Population
From November 1999 to June 2001, patients admitted to our
institution for CABG who appeared to be good candidates for
off-pump surgery were offered the option to participate in the
study. Written informed consent was obtained from all recruited
patients after explanation of the potential risks and benefits of the
study. The study was approved and monitored by the Ethics
Committee of the Research Center of the Montreal Heart Institute.
Exclusion criteria consisted of preoperative known coagulopathy,
patients unable to give an informed consent, and patients with
contraindications to OPCABG (ie, small coronary arteries, in-
tramyocardial arteries, associated valve procedures, and hemody-
namic unstablility).
Operative Procedure
Perioperative management was standardized in the 2 groups. OP-
CABG was performed with the use of commercially available myo-
cardial stabilizers and previously reported surgical techniques.10,11 In
the control group heparin was administered as a 1 mg/kg bolus and
was reversed with a 1 mg/kg dose of protamine sulfate after CABG.
In the treated group danaparoid was administered as a 40 U/kg bolus,
and a placebo was injected after CABG. Heparin, danaparoid, prota-
mine, and the placebo injections were prepared by the hospital phar-
macists and were administered blind to all physicians.
In both groups mediastinal drainage was achieved with a com-
mercially available autotransfusion system.
Postoperative Transfusion
Postoperative homologous blood products were administered ac-
cording to the following criteria during the study period. The
threshold for homologous red blood cell transfusion was 80 g/L.
Clotting factors were administered for persistent bleeding only
after discussion with our hematology consultant, who had access to
the code of randomization if needed. Four units of fresh frozen
plasma were given for persistent moderate (100-300 mL/h) or
severe (300 mL/h for 2 hours) bleeding with an international
normalized ratio of greater than 1.8. For bleeding patients with
platelet counts of less than 80  109/L, 8 units of platelets were
transfused, and 8 units of cryoprecipitate were administered for
fibrinogen levels of less than 1.0 g/L.
Safety Measurement of Anticoagulant Activity and
Myocardial Damage
Serum cardiac troponin T levels were measured 24 and 48 hours
after CABG to determine the overall ischemic damage in both
groups.12 Anti-Xa activity was also measured in the 2 groups of
patients 30 minutes and 12 hours after administration of the study
drugs to determine antithrombotic activity. The laboratory was
unblinded to permit dosage of anti-Xa level appropriate with the
anticoagulant used. Because danaparoid and unfractionated hepa-
rin have their own specific anti-Xa activity, heparin and danap-
aroid were used independently for calibration of standard curves.
The biologic activity of both anticoagulants resides in their ability
to accelerate the inhibitory effect of antithrombin on coagulation
proteases. We used the IL test heparin kit (Instrumentation Labo-
ratory, Lexington, Mass), which is based on a synthetic chromo-
genic substrate and on factor Xa inactivation. Anti-Xa level in
patients is measured on ACL 3000 (Beckman Coulter, Inc) in 2
stages. First, to obtain a constant concentration of antithrombin III,
purified antithrombin III is added to the tested plasma. Factor Xa
is then added to the tested plasma in excess and is neutralized by
heparin-antithrombin III of danaparoid-antithrombin III. Second,
residual factor Xa is then quantified with a synthetic chromogenic
substrate and is inversely proportional to the anti-Xa activity in the
sample.
Statistical Analysis
The study was designed to demonstrate equivalence in the post-
operative blood loss values on the basis of our earlier experience
with OPCABG.10,13 It was estimated that 120 patients had to be
randomized into 2 groups. Patients were randomized to the heparin
group or the danaparoid group by use of a table of random digits by
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blocks of 4. The study was stopped for a preliminary analysis of the
primary and secondary end points after enrolling 71 patients because
it appeared clinically that some patients were administered a greater
number of homologous blood transfusions compared with data from
our earlier experience with patients undergoing OPCABG.10,13
Blood tests and different measurements of standardized data
were done according to a strict protocol identical in both groups.
All data were prospectively collected from the chart of every
enrolled patient by 3 research assistants. For the purpose of the
study, the term transfusion refers to any administration of homol-
ogous blood products, including homologous packed red blood cell
units, platelets, fresh frozen plasma, and cryoprecipitate units.
Data are expressed as means, SDs, and 95% confidence limits
(CLs) when specified. Statistical comparisons were done with the
unpaired Student t test, the 2 test, and the Fischer exact test.
Relative risk and the 95% CL was calculated to study the exposure
of patients of the 2 groups to homologous blood transfusions.
Univariate and multiple logistic regression analyses were per-
formed to identify the relationship between the need for homolo-
gous blood transfusion and several clinical variables in the 2
groups. Data analysis was performed with the Number Cruncher
Statistical System 2001 (NCSS Statistical Software).
Results
Patients in the danaparoid and heparin groups were similar
for all clinical and demographic parameters (Table 1). Most
patients had triple-vessel coronary artery disease, and 38%
to 56% of patients were administered intravenous heparin
until the time of the operation because of unstable angina.
Between 40% and 50% of patients were also administered
aspirin before the operation (Table 1).
The numbers of CABGs averaged 2.6  0.7 and 2.5 
0.9 in patients receiving danaparoid and heparin, respec-
tively (P  .8, Table 2). The duration of the operation and
the intraoperative blood losses were similar in the 2 groups.
There was no conversion to CPB in either group.
Although the hemoglobin levels and platelet counts were
similar between the 2 groups before the operation, the
hemoglobin level was significantly lower in patients with
danaparoid during the first day after the operation compared
with that in patients receiving heparin (Table 3). The acti-
vated clotting time during the operation was also signifi-
cantly lower among patients who were administered danap-
aroid during CABG. Initially, the measure of anti-Xa
activity was similar in the 2 groups during the operation, but
the anti-Xa activity was higher in patients receiving danap-
aroid compared with in patients receiving heparin 12 hours
after the operation (Table 3).
The postoperative amount of blood drained from the
mediastinum averaged 1394  1033 mL (95% CL, 1034-
1755 mL) in patients receiving danaparoid compared with
1130  868 mL (95% CL, 836-1424 mL) in patients re-
ceiving heparin (P  .2). Although the mean number of
homologous blood products transfused per patient was sim-
ilar in the 2 groups, 53% of the patients receiving danap-
aroid were administered homologous blood products com-
pared with 27% of the patients receiving heparin, which was
a significant difference (P  .03, Table 4).
Serum troponin T levels averaged 0.5  0.6 and 0.5  0.6
g/L 24 and 48 hours after OPCABG in patients receiving
danaparoid compared with 0.5  1 g/L (P  .8) and 0.4 
0.6 g/L (P  .4) in patients receiving heparin, respectively.
There was one patient with a perioperative myocardial infarc-
tion in each group (1/34 [3%] and 1/37 [3%], respectively).
One patient with severe Parkinson disease before the operation
underwent OPCABG with danaparoid and showed generalized
convulsions and coma for a few days after the operation but
recovered completely thereafter. One patient in the danaparoid
group (1/34 [3%]) required surgical re-exploration for exces-
sive mediastinal bleeding after CABG. Length of stay in the
intensive care unit and in the hospital averaged 2 1 and 5
1 days, respectively, in patients receiving danaparoid and 2 
3 days (P  .8) and 6  3 days (P  .6), respectively, in
patients receiving heparin. There was no death in either group.
Univariate analyses performed to study risk factors re-
lated with blood transfusions in OPCABG showed that
women with lower hemoglobin levels before CABG and the
use of danaparoid were associated with higher transfusion
requirements after the operation (Table 5). In a multivari-
able analysis the use of danaparoid remained the only risk
factor significantly related to the need for blood transfusion
after OPCABG (Table 6).
Discussion
The present double-blind, randomized clinical trial compar-
ing the anticoagulants danaparoid and heparin in OPCABG
demonstrated a 26% increase (relative risk, 2; 95% CL, 1-4)
in the percentage of patients exposed to homologous blood
products with the use of danaparoid. Although blood losses
were similar during the operation, postoperative mediastinal
blood drainage was higher in patients receiving danaparoid.
The measure of anti-Xa activity remained high 12 hours
after CABG in patients receiving danaparoid compared with
TABLE 1. Clinical and angiographic characteristics of patients
No. of patients
Danaparoid
(n  34)
Heparin
(n  37) P value
Age (y) 68 9 65 10 .3
Men/women 26/8 31/6 .4
Stable/unstable angina 22/12 18/19 .2
Recent MI 4 7 .4
Left main stenosis 5 9 .4
Single-vessel disease 3 2 .7
Two-vessel disease 10 14 .6
Three-vessel disease 21 21 .8
LV dysfunction 4 5 .9
Preoperative intravenous heparin 19 14 .2
Preoperative aspirin (within 7 d) 17 15 .5
MI, Myocardial infarction; LV, left ventricular.
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almost no anti-Xa activity in those receiving heparin, indi-
cating that, in the latter patients, the protamine was effective
in neutralizing the effect of heparin as opposed to the
placebo used in the danaparoid group. The persistence of
anti-Xa activity with danaparoid explains the higher blood
losses and the higher requirement for homologous blood
transfusions in this group.
Although mediastinal blood loss and the need for trans-
fusions were higher in patients with danaparoid compared
with in those with heparin (53% vs 27%, respectively), we
have showed, in a recent study on reinfusion of mediastinal
blood after on-pump cardiac surgery, that 55% of the reinfused
patients were administered homologous blood products after
the operation.14 Thus, our group of off-pump patients receiving
a low dose of the anticoagulant danaparoid showed similar
blood losses and received a similar number of homologous
blood products after the operation when compared with a
group of on-pump patients receiving heparin.14
Several authors have suggested that OPCABG with the
use of heparin results in a decrease in the use of homologous
blood products when compared with that seen in patients
undergoing operations with the CPB system.8,9 Results of
the present study corroborate these reports. Only 27% of
patients who underwent OPCABG with heparin required
TABLE 2. Intraoperative characteristics
Danaparoid
(n  34)
Heparin
(n  37) P value
No. of grafts per patient 2.6 0.7 2.5 0.9 .8
Duration of the operation (min) 146 36 140 41 .5
Conversion to CPB 0 0
Intraoperative blood loss (mL) 485 346 478 282 .9
Cardiac index (L-min-m–2)
Before the operation 2.6 0.6 2.5 0.5 .6
After the operation 2.7 0.7 2.6 0.6 .6
TABLE 3. Coagulation and blood profile
Danaparoid
(n  34)
Heparin
(n  37) P value
Hemoglobin before the operation (g/L) 129 15 134 18 .2
Hemoglobin POD 1 (g/L) 90 12 97 13 .02
Platelets before the operation ( 109/L) 240 60 238 84 .9
Platelets POD 1 (109/L) 161 53 167 57 .7
ACT during the operation (s) 223 103 394 150 .001
Anti-Xa activity (U/mL)
30 min after intravenous injection 1.6 0.6 1.9 0.8 .1
12 h after intravenous injection 0.3 0.1 0.04 0.08 .001
Troponin T serum levels (g/L)
24 h after CABG 0.5 0.6 0.5 1 .8
48 h after CABG 0.5 0.6 0.4 0.6 .4
POD, Postoperative day; ACT, activated clotting time.
TABLE 4. Exposure to homologous blood products
Danaparoid
(n  34)
Heparin
(n  37) P value
Packed red blood cells 1.3 1.7 0.7 1.4 .1
Platelets 1.1 2.3 0.9 2.6 .8
Fresh frozen plasma 0.8 2 0.3 1 .2
Cryoprecipitate 0.5 2.7 0 .3
Total 3.6 7 1.9 4 .2
Patients transfused (%) 18 (53%) 10 (27%) .03
TABLE 5. Univariate analysis of the determinants of trans-
fusion requirement for all patients
Characteristics Odds ratio 95% CL P value
Sex (women) 5.42 1.49-19.62 .01
Hemoglobin level (g/L) 0.965 0.949-0.984 .035
Use of danaparoid 3.04 1.13-8.17 .027
TABLE 6. Multivariable analysis of the determinants of
transfusion requirement for all patients
Characteristics Odds ratio 95% CL P value
Sex (women) 3.62 0.77-17.1 .1
Hemoglobin level (g/L) 0.98 0.96-1.03 .4
Use of danaparoid 3.71 1.22-11.25 .02
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homologous blood products after the operation, the lowest
rate that our group has reported in recent years.14
Increased activated clotting time and anti-Xa activity
values during surgical intervention in the 2 groups suggest
that the antithrombotic effect of the 2 drugs was adequate
during the operation. The higher blood losses and transfu-
sion requirements in patients receiving danaparoid appear
related to the prolonged and nonreversible effect of the
drug. However, serum troponin T levels were similar in the
2 groups after CABG, suggesting that the overall ischemic
damage was identical in the 2 groups.
Although the present results show a significant increase
in the requirement of blood transfusions in patients who
undergo OPCABG with danaparoid, we suggest that this
approach is a valuable alternative to unfractionated heparin
and CPB in patients with serious contraindications to the
use of heparin. Bauer and colleagues15 reported that one
fifth of patients undergoing CPB surgery have heparin-
induced platelet antibodies detectable before the procedure
as result of prior exposure to heparin, and several more had
antibodies after the operation. Heparin is far more immu-
nogenic than has been appreciated.16 Walls and coworkers17
and Singer and associates18 reported that unrecognized HIT
in patients undergoing CPB results in serious bleeding and
thromboembolic complications after the operation.
Other anticoagulants have been used as alternatives to hep-
arin in patients undergoing CPB, but danaparoid is the drug
most often used in clinical practice.1,2 Because high doses of
danaparoid in patients with CPB appears to result in bleeding
complications after the operation, we chose a lower dose of
danaparoid and an off-pump approach for CABG.1 The peak
anti-Xa activities measured in our patients with danaparoid are
similar to levels reported by Frederiksen1 in reviewing the
surgical literature of patients undergoing operations with
danaparoid. Yet mediastinal drainage and transfusion re-
quirements remained higher with the use of danaparoid
compared with heparin because of the long half-life and the
absence of a specific antidote to the former drug.
Follis and Schmidt2 suggested that the simplest strategy
in patients with heparin-induced antibodies is to postpone
the operation for 6 to 8 weeks and monitor the level of
antibodies. Some reports suggest that it is safe to proceed
with heparin if there are no antibodies. We suggest that
OPCABG with danaparoid is a valuable alternative in pa-
tients in whom the wait appears to increase the surgical risk.
In conclusion, patients who underwent OPCABG with
low-dose danaparoid were at greater risk of exposure to
homologous blood products and required a greater number
of transfusions compared with patients who underwent off-
pump surgery with heparin. Antithrombotic activity was
identical, and ischemic damage after CABG was also sim-
ilar between drugs. Although a larger percentage of patients
receiving danaparoid required blood transfusions, the per-
centage of patients being transfused with danaparoid OP-
CABG is similar to numbers seen in previous reports with
CPB and heparin. Thus, OPCABG with danaparoid is a safe
alternative in patients with HIT requiring CABG.
The present study suggest that OPCABG offers new
approaches and valuable alternatives to patients who present
preoperative risk factors associated with high morbidity
when the operation is performed by using a more conven-
tional approach with CPB. We suggest that HIT in patients
who need immediate CABG is an indication for the use of
OPCABG techniques and the anticoagulant danaparoid.
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